Dec 23 (Reuters) - The U.S. Food and Drug Administration

has revoked the emergency use authorization for four COVID-19

antibody-based drugs, including those from Eli Lilly ( LLY ) and

Regeneron.

The shelf life of the drugs had expired and they had not

been authorized for administration to patients for more than a

year due to the circulation of non-susceptible variants, the FDA

said in letters dated earlier this month and posted on its

website on Monday.

The FDA revoked the authorization for Lilly's bebtelovimab,

AstraZeneca's ( AZN ) Evusheld, GSK's sotrovimab and

Regeneron's REGEN-COV.

The companies also do not intend to offer the products in

the U.S. anymore, according to the FDA.

The FDA said the companies would notify customers and

providers about the revocation with instructions for product

destruction or return.